I have invested in many pre-revenue bio techs and I can

New Post Public Reply Private Reply Replies (0) Message Board
CyberC
300
I have invested in many pre-revenue bio techs and I can tell you that I have not seen one that has come through on time lines on their trial results. It's the nature of the game.

As far as ENDV goes, I have friend that has invested in a PP here and he speaks w/ Mr. Mann weekly. While he is very guarded in what he says, I can tell w/ 100% certainty that he is buying the shares on the open market w/ his own money. Look at the filings for the Executive compensation here. These guys aren't padding their bank accounts thru large salaries. Also, look at their qualifications...these guys know what they are doing. Mr. Mann is loading shares for his family. He already owns 20 plus million shares and is loading more each and every week......

The conspiracy theories around why he is adding are beyond ridiculous. He purposely adds in small increments because HE DOESN'T WANT TO ARTIFICIALLY INFLATE THE PPS.

If his intention was to inflate the PPS by filing Form 4's, he would've abandoned that strategy months ago or certainly changed his startegy on the amounts he purchases w/ each buy because it obviously hasnt worked.....look at the price points he has bought at this year.

Step away for a minute and put yourself in his shoes. If he was buying shares by propping up the PPS w/ huge ask slaps, the other members of the Executive Team would be lighting his ass up......he wants as many shares as he can get w/out disrupting the normal flow of trading so he is not called into question. He doesn't care if it's .10 or .02 he WANTS MORE SHARES!!!!

Read the tea leaves and make zip code changing money or fall prey to the uninformed Ihub hack posts. The choice is yours. I am in deep and I'm not here to lose.

Thank you Commoncents3

Re: BlackDoggie Post

Endonovo Therapeutics, Inc. (ENDV) Stock Research Links

ENDV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Celebrating Cultural Excellence: Fukuoka Prize 2025 Laureates Revealed

Updated Category News Views 360

Fukuoka City Announces 2025 Fukuoka Prize Winners Fukuoka City has revealed the recipients of the prestigious Fukuoka Prize for 2025, honoring remarkable individuals in the field of Asian studies and the arts. This award is presented to those who excel in preserving and enhancing the rich tapestry of Asian culture. Fukuoka City is dedicated to celebrating these...

Continue Reading
Investors Unite: Join Flywire Corporation Legal Action Today

Updated Category News Views 168

Flywire Corporation Investors Take Action Against Securities Fraud In a moment of reckoning, investors in Flywire Corporation are seizing the opportunity to join a class action lawsuit concerning alleged securities fraud. The filing of this lawsuit has been initiated to hold accountable those responsible for misleading investors during a specified period, marking a...

Continue Reading
Venus Concept Secures $2.7 Million for Growth and Innovation

Updated Category News Views 323

Venus Concept Raises Significant Funds for Future Endeavors Venus Concept Inc. (NASDAQ: VERO), a renowned name in the global medical aesthetic technology arena, recently achieved a noteworthy milestone by closing a registered direct offering that provided around $1.57 million in gross proceeds. The offering consisted of 386,700 shares of common stock, sold at $4.06 each,...

Continue Reading
Revolutionary RAGE: UPENDS Launches Game-Changing Vape System

Updated Category News Views 211

UPENDS Unveils Groundbreaking Open Pod Vape System In a remarkable stride forward for the vaping industry, UPENDS has launched their revolutionary RAGE open pod system, designed to transform how enthusiasts experience vaping. As the European market continues to evolve, this cutting-edge device positions itself as a leader in user-centric innovation and compliance. The...

Continue Reading
Investors Target Kyverna Therapeutics: Key Details You Need

Updated Category News Views 101

Understanding Ongoing Investigations at Kyverna Therapeutics As the financial landscape continues to evolve, investors find themselves keenly interested in the developments surrounding Kyverna Therapeutics, Inc. (NASDAQ: KYTX). With a prominent law firm engaged in scrutinizing potential claims, the situation promises vital updates for concerned stakeholders. Faruqi &...

Continue Reading